Interius BioTherapeutics is pioneering innovative approaches in the field of cell and gene therapy, particularly through its development of in vivo chimeric antigen receptor (CAR) T cell therapies. The company’s platform, based on research from Dr. Saar Gill at the University of Pennsylvania, enables the direct engineering of CAR T cells within the human body, eliminating the need for ex vivo manipulations and the associated toxic pre-conditioning chemotherapy typically required in standard CAR T treatments. This novel method aims to enhance the specificity and efficacy of therapies for hematologic malignancies, particularly B-cell malignancies, by utilizing a targeted lentiviral vector technology that allows for precise delivery of genetic material to the appropriate cells.

Interius is advancing its lead candidate, INT2104, which is designed to generate CAR T and natural killer (NK) cells in vivo, specifically targeting CD20-positive B cells. This investigational therapy is characterized as an off-the-shelf solution, administered through a single intravenous infusion without the need for lymphodepletion or specialized equipment. The company is also exploring applications beyond immuno-oncology, including potential treatments for autoimmune diseases, thereby broadening the scope of its gene therapy modalities. With regulatory approvals in place for clinical trials, Interius is positioned to make significant strides in delivering transformative therapies to patients in need.

United States

Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.

Interius BioTherapeutics

Company Details